

Envision Healthcare Holdings, Inc.  
Form 8-K  
November 16, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

---

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

---

Date of Report (Date of earliest event reported): **November 16, 2016 (November 16, 2016)**

**ENVISION HEALTHCARE HOLDINGS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction)

**001-36048**  
(Commission)

**45-0832318**  
(IRS Employer)

Edgar Filing: Envision Healthcare Holdings, Inc. - Form 8-K

of incorporation)

File Number)

Identification No.)

**6363 South Fiddler s Green Circle, 14th Floor,  
Greenwood Village, Colorado**  
(Address of principal executive offices)

**80111**  
(Zip Code)

**(303) 495-1200**

(Each registrant s telephone number, including area code)

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On November 16, 2016, in connection with the proposed merger of Envision Healthcare Holdings, Inc. ( Envision ) and AmSurg Corp. ( AMSURG ) (the Merger ), each of Envision and AMSURG issued a press release announcing that AMSURG 's wholly-owned subsidiary, New Amethyst Corp., to be renamed Envision Healthcare Corporation (the Company ), has priced the private offering of \$550,000,000 aggregate principal amount of its 6.25% Senior Notes due 2024 (the Notes ) in transactions that are exempt from registration under the Securities Act of 1933, as amended (the Securities Act ). The offering is expected to close on December 1, 2016, subject to customary closing conditions. If the closing of the Notes occurs prior to the date of the completion of the Merger, the proceeds of the offering of the Notes will be deposited into an escrow account pending the consummation of the Merger. A copy of the press release is furnished as Exhibit 99.1 to this report.

The Company intends to use the net proceeds from the offering, together with borrowings of \$3,495,000,000 expected to be made under a new term loan facility to be entered into by Envision Healthcare Corporation ( EHC ), an indirect wholly-owned subsidiary of Envision, (i) to repay EHC 's existing indebtedness under its term loan and asset-based facilities, (ii) to purchase or redeem AMSURG 's 5.625% senior notes due 2020, (iii) to repay AMSURG 's existing indebtedness under its term loan and revolving loan facilities, (iv) to pay transaction fees and expenses and (v) for working capital. Upon the consummation of the Merger, the Company will assume the obligations of EHC under the new term loan facility, and the Notes will be guaranteed by the Company 's domestic subsidiaries that will guarantee the new term loan facility. This report does not constitute an offer to sell or a solicitation of an offer to purchase the Notes or any other security. The Notes have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description of Exhibit</b>
99.1	Press Release of Envision Healthcare Holdings, Inc. and AmSurg Corp. Announcing Pricing of Senior Notes Offering, dated November 16, 2016.

**Forward-Looking Statements**

Certain statements and information in this Current Report on Form 8-K may be deemed to be forward-looking statements within the meaning of the Federal Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to Envision 's and AMSURG 's objectives, plans and strategies, and all statements (other than statements of historical facts) that address activities, events or developments that Envision and AMSURG intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as believe, hope, may, anticipate, should, intend, plan, will, expect, estimate, positioned, strategy and similar expressions, and are based on assumptions and assessments made by Envision 's and AMSURG 's management in light of their experience and their perception of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. Any forward-looking statements in this Current Report on Form 8-K are made as of the date hereof, and Envision and AMSURG undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance. Whether actual results will conform to expectations and predictions is subject to known and unknown risks and uncertainties, including: (i) risks and uncertainties discussed in the reports that Envision and AMSURG have filed with the SEC; (ii) general economic, market, or business conditions; (iii) risks associated with the ability to consummate the business

## Edgar Filing: Envision Healthcare Holdings, Inc. - Form 8-K

combination between Envision and AMSURG and the timing of the closing of the business combination; (iv) the ability to successfully integrate Envision's and AMSURG's operations and employees; (v) the ability to realize anticipated benefits and synergies of the business combination; (vi) the potential

impact of announcement of the business combination or consummation of the transaction on relationships, including with employees, customers and competitors; and (vii) other circumstances beyond Envision's and AMSURG's control. Refer to the section entitled "Risk Factors" in Envision's and AMSURG's annual, quarterly and other periodic reports for a discussion of important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements.

#### **No Offer or Solicitation / Additional Information and Where to Find It**

This Current Report on Form 8-K is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the proposed business combination between Envision and AMSURG or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. The proposed business combination between Envision and AMSURG will be submitted to their respective shareholders on November 28, 2016 for consideration. On August 4, 2016, AMSURG caused its newly formed, wholly owned subsidiary, the Company, to file with the Securities and Exchange Commission (the "SEC") a Registration Statement on Form S-4 (File No. 333-212885) that constitutes a prospectus of the Company and a joint proxy statement of Envision and AMSURG. The SEC declared the Form S-4, as subsequently amended, effective on October 19, 2016. Envision and AMSURG have caused the definitive joint proxy statement/final prospectus to be mailed to their respective shareholders, as required by applicable law. This Current Report on Form 8-K is not a substitute for the definitive joint proxy statement/final prospectus, or any other document that may be filed with the SEC in connection with the proposed business combination. Investors and shareholders are urged to read carefully and in their entirety the definitive joint proxy statement/final prospectus delivered to shareholders, and any other relevant documents that are filed with the SEC when they become available, because they contain important information about the proposed business combination and related matters. Investors and shareholders may obtain free copies of the definitive joint proxy statement/final prospectus and other documents containing important information about Envision, AMSURG and the Company, once such documents are filed with the SEC, through the website maintained by the SEC at [www.sec.gov](http://www.sec.gov). Envision and AMSURG make available free of charge at [www.evhc.net](http://www.evhc.net) and [www.amsurg.com](http://www.amsurg.com), respectively (in the "Investors" section), copies of materials they file with, or furnish to, the SEC.

#### **Participants in The Merger Solicitation**

Envision, AMSURG and certain of their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from the stockholders of Envision and shareholders of AMSURG in connection with the proposed business combination. Information about the directors and executive officers of Envision is set forth in its proxy statement for its 2016 annual meeting of stockholders filed with the SEC on March 23, 2016. Information about the directors and executive officers of AMSURG is set forth in its proxy statement for its 2016 annual meeting of shareholders filed with the SEC on April 22, 2016 and its Annual Report on Form 10-K for the year ended December 31, 2015 filed with the SEC on February 25, 2016. These documents can be obtained free of charge from the sources indicated above. Other information regarding those persons who are, under the rules of the SEC, participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, are included in the definitive joint proxy statement/final prospectus.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ENVISION HEALTHCARE HOLDINGS, INC.**  
(Registrant)

November 16, 2016

By:

/s/ Craig A. Wilson  
Craig A. Wilson  
Senior Vice President, General Counsel and Secretary